The ICR at a glance

The Institute of Cancer Research, London, is one of the world’s most influential cancer research organisations. We are a research institute, a higher education institution and a charity, and our mission is to make the discoveries that defeat cancer.

We are world leaders in understanding the genetics and fundamental biology of cancer, the discovery and translational development of innovative targeted cancer drugs and biomarkers, and the clinical development of new forms of high-precision radiotherapy and immunotherapy.

Since 2005 the ICR has discovered 20 drug candidates – more than any other academic research centre in the world.

The ICR is the top-ranked higher education institution in the UK for the quality and impact of its research.

Together with our partner hospital The Royal Marsden, we are ranked in the top four centres for cancer research and treatment worldwide.

We have 100 active partnerships with a range of companies, and we are the most successful higher education institution in the UK at generating invention income from our research.

The ICR is a proud member of the Athena SWAN Charter and has held a Silver Award since 2016. In 2019 our Silver Award was renewed until 2023 to recognise our progress in creating an open, diverse and fully inclusive working environment.

The ICR is the most successful higher education institution in the UK at earning invention income from its research per member of research staff.

In 2018/19 we had a total income of £167.4 million and our total expenditure was £143.3 million.

We spent £136.1m, or 95 per cent, of our expenditure on research activity.

In 2018/19 we employed 1,108 staff. Over the academic year, there were 200 students registered in research degrees and 141 MSc students with the ICR.

We are world leaders in understanding the genetics and fundamental biology of cancer, the discovery and translational development of innovative targeted cancer drugs and biomarkers, and the clinical development of new forms of high-precision radiotherapy and immunotherapy.

The ICR provides scientists and clinicians with world-class postgraduate education in cancer research and treatment.

The joint ICR and Royal Marsden Drug Development Unit is one of the leading and largest phase I clinical trials centres in the world.

The ICR is the top-ranked higher education institution in the UK for the quality and impact of its research.

Together with our partner hospital The Royal Marsden, we are ranked in the top four centres for cancer research and treatment worldwide.

The ICR is a proud member of the Athena SWAN Charter and has held a Silver Award since 2016. In 2019 our Silver Award was renewed until 2023 to recognise our progress in creating an open, diverse and fully inclusive working environment.

The ICR is the most successful higher education institution in the UK at earning invention income from its research per member of research staff.

In 2018/19 we had a total income of £167.4 million and our total expenditure was £143.3 million.

We spent £136.1m, or 95 per cent, of our expenditure on research activity.

In 2018/19 we employed 1,108 staff. Over the academic year, there were 200 students registered in research degrees and 141 MSc students with the ICR.